Genoptix, Inc.
Genoptix, Inc., a prominent player in the diagnostics industry, is headquartered in the United States. Founded in 2006, the company has established itself as a leader in providing advanced laboratory services, particularly in oncology and haematology. With a focus on personalised medicine, Genoptix offers a range of innovative diagnostic solutions that enhance patient care and treatment outcomes. The company operates primarily in the US, serving healthcare providers with its state-of-the-art testing services. Genoptix is renowned for its commitment to quality and accuracy, utilising cutting-edge technology to deliver timely and reliable results. Notable achievements include its recognition for excellence in laboratory practices, positioning it as a trusted partner in the healthcare community. Through its dedication to advancing cancer diagnostics, Genoptix continues to make significant contributions to the field.
DitchCarbon Score
How does Genoptix, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Genoptix, Inc.'s score of 26 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Genoptix, Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. The company is a current subsidiary of NeoGenomics, Inc., which may influence its climate commitments and performance metrics. As of now, Genoptix has not established any documented reduction targets or initiatives, nor does it participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). This lack of data suggests that Genoptix may still be in the early stages of developing its climate strategy or reporting framework. Given the absence of specific emissions data and reduction commitments, it is essential for Genoptix to consider implementing robust sustainability practices and setting measurable targets to align with industry standards and expectations. This would not only enhance their environmental performance but also contribute positively to the broader climate action efforts within the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | |
|---|---|
| Scope 1 | 536,000 |
| Scope 2 | 4,181,000 |
| Scope 3 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Genoptix, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
